

Antiphospholipid syndrome in pregnancy: A controlled treatment trial

Submission date 23/01/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 23/01/2004	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 12/01/2010	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Roy Farquharson

Contact details
Liverpool Women's Hospital
Crown Street
Liverpool
United Kingdom
L8 7SS
+44 (0)151 708 9988
Roy.Farquharson@lwh-tr.nwest.nhs.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
RHC18084

Study information

Scientific Title

Study objectives

To assess the efficacy of low dose heparin in the treatment of antiphospholipid antibody syndrome during pregnancy, comparing low dose aspirin with low dose aspirin combined with low molecular weight heparin, in women suffering from recurring pregnancy loss.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Pregnancy; antiphospholipid antibody syndrome

Interventions

1. Aspirin
2. Aspirin and low molecular weight heparin

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Live birth rate in both arms of the trial (defined as the live birth rate after 24 weeks gestation).

Secondary outcome measures

The secondary outcome measures will concern maternal morbidity, e.g. osteoporosis, and fetal parameters, such as premature delivery and the incidence for "small for dates".

Overall study start date

01/01/1998

Completion date

01/01/2000

Eligibility

Key inclusion criteria

Pregnant women with antiphospholipid antibody syndrome

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

98 (added 12/01/10; see publication)

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/01/1998

Date of final enrolment

01/01/2000

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Liverpool Women's Hospital

Liverpool

United Kingdom

L8 7SS

Sponsor information

Organisation

NHS R&D Regional Programme Register - Department of Health (UK)

Sponsor details

The Department of Health
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL
+44 (0)20 7307 2622
dhmail@doh.gsi.org.uk

Sponsor type

Government

Website

<http://www.doh.gov.uk>

Funder(s)

Funder type

Government

Funder Name

NHS Executive North West (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/09/2002		Yes	No